利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

12 条记录 (耗时 0.026 秒)

    PIPERIDINE DERIVATIVE, PIPERAZINE DERIVATIVE AND AGENT FOR TREATMENT OF DISEASE INVOLVING CENTRAL NERVOUS SYSTEM DISORDERS
    1.
    发明申请
    PIPERIDINE DERIVATIVE, PIPERAZINE DERIVATIVE AND AGENT FOR TREATMENT OF DISEASE INVOLVING CENTRAL NERVOUS SYSTEM DISORDERS 审中-公开
    哌啶衍生物，哌嗪衍生物和治疗涉及中枢神经系统疾病的疾病

    公开(公告)号：US20110263862A1

    公开(公告)日：2011-10-27

    申请号：US13126158

    申请日：2009-10-26

    申请人： Shiro Mita ,  Naoyuki Kobayashi

    发明人： Shiro Mita ,  Naoyuki Kobayashi

    IPC分类号： C07D221/00

    CPC分类号： C07D211/14 ,  C07D295/02 ,  C07D295/033

    摘要： A novel piperidine derivative and a novel piperazine derivative which are useful as novel sigma receptor ligands, and an agent for treatment of diseases involving a central nervous system disorders, said agent containing one of the compound as an active ingredient. The agent contains a compound represented by general formula (I) or a pharmacologically acceptable salt thereof as an active ingredient: wherein X represents an alkylene group having 1 to 5 carbon atoms, and the alkylene group may be substituted by one or more alkyl groups each having 1 to 2 carbon atoms; Y represents a carbon atom or a nitrogen atom; and R1 and R2 each independently represents a hydrogen atom, a halogen atom, an alkyl group having 1 to 2 carbon atoms or an alkoxy group having 1 to 2 carbon atoms.

    摘要翻译： 可用作新型σ受体配体的新型哌啶衍生物和新型哌嗪衍生物，以及用于治疗涉及中枢神经系统疾病的疾病的药剂，所述药剂含有该化合物之一作为活性成分。 该试剂含有由通式（I）表示的化合物或其药学上可接受的盐作为活性成分：其中X表示碳原子数为1〜5的亚烷基，亚烷基可以各自被一个以上的烷基取代 具有1至2个碳原子; Y表示碳原子或氮原子; R 1和R 2各自独立地表示氢原子，卤素原子，碳原子数1〜2的烷基或碳原子数1〜2的烷氧基。

    Piperazine derivatives
    3.
    发明授权
    Piperazine derivatives 失效
    哌嗪衍生物

    公开(公告)号：US07985751B2

    公开(公告)日：2011-07-26

    申请号：US11989952

    申请日：2006-08-02

    申请人： Connie Sun

    发明人： Connie Sun

    IPC分类号： C07D241/04 ,  A61K31/50

    CPC分类号： C07D295/096 ,  C07D295/03 ,  C07D295/033 ,  C07D295/073 ,  C07D317/58

    摘要： Compounds of general formula (I) in which R1 and R0 have any of the meanings given in the specification have affinity for sigma receptors and are useful in the treatment of disorders of the central nervous system.

    摘要翻译： 其中R1和R0具有本说明书中给出的任何含义的通式（I）的化合物对σ受体具有亲和力，并且可用于治疗中枢神经系统疾病。

    Sigma ligands for neuronal regeneration and functional recovery
    4.
    发明授权
    Sigma ligands for neuronal regeneration and functional recovery 失效
    Sigma配体用于神经元再生和功能恢复

    公开(公告)号：US07863272B2

    公开(公告)日：2011-01-04

    申请号：US10868423

    申请日：2004-06-14

    申请人： Donna Oksenberg ,  Roman Urfer

    发明人： Donna Oksenberg ,  Roman Urfer

    IPC分类号： A61K31/50 ,  A01N43/60

    CPC分类号： C07D295/096 ,  A61K31/00 ,  A61K31/438 ,  A61K31/495

    摘要： The invention discloses methods and compositions useful for facilitating neuronal regeneration and functional recovery in neurodegenerative diseases. The methods and compositions utilize ligands for the sigma receptor, wherein the ligand is preferably SA-4503, or salts, or solvates thereof. These molecules can be delivered alone or in combination with agents which treat or prevent neurodegenerative diseases such as those caused by ischemic stroke, diabetic peripheral neuropathy, cancer therapy induced neuropathy, multiple sclerosis, amyotrophic lateral sclerosis, traumatic brain injury, spinal cord injury, Huntington's disease or Parkinson's disease. In other methods, the sigma receptor ligands are administered after stroke to facilitate functional recovery. The administration of the sigma receptor ligands effects faster functional recovery.

    摘要翻译： 本发明公开了用于促进神经退行性疾病中的神经元再生和功能恢复的方法和组合物。 所述方法和组合物利用配体用于σ受体，其中配体优选为SA-4503，或其盐或溶剂化物。 这些分子可以单独递送或与治疗或预防神经变性疾病如由缺血性卒中，糖尿病性周围神经病变，癌症治疗诱发的神经病变，多发性硬化，肌萎缩性侧索硬化，创伤性脑损伤，脊髓损伤，亨廷顿舞蹈症 疾病或帕金森病。 在其他方法中，σ受体配体在中风后施用以促进功能恢复。 σ受体配体的施用使功能恢复更快。

    CYCLOHEXYLAMINE DERIVATIVE CONTAINING PHENYL GROUP, AND THERAPEUTIC AGENT FOR DISEASES ACCOMPANIED BY CENTRAL NERVOUS SYSTEM DISORDERS
    7.
    发明申请
    CYCLOHEXYLAMINE DERIVATIVE CONTAINING PHENYL GROUP, AND THERAPEUTIC AGENT FOR DISEASES ACCOMPANIED BY CENTRAL NERVOUS SYSTEM DISORDERS 审中-公开
    环己基胺衍生物含有苯基，以及中枢神经系统疾病伴发的疾病治疗药物

    公开(公告)号：US20110257225A1

    公开(公告)日：2011-10-20

    申请号：US13126162

    申请日：2009-10-26

    申请人： Shiro Mita ,  Naoyuki Kobayashi

    发明人： Shiro Mita ,  Naoyuki Kobayashi

    IPC分类号： A61K31/47 ,  A61P25/00 ,  A61P25/16 ,  A61P25/28 ,  A61K31/138 ,  A61K31/137

    CPC分类号： C07C217/16 ,  C07C211/40 ,  C07C217/20 ,  C07C217/62 ,  C07C323/25 ,  C07C2601/14 ,  C07D215/06

    摘要： Disclosed is a novel cyclohexylamine derivative containing a phenyl group, which is useful as a novel sigma receptor ligand. Also disclosed is a therapeutic agent for diseases accompanied by a central nervous system disorder, which comprises the compound as an active ingredient. The therapeutic agent comprises a compound represented by general formula [1] or a pharmacologically acceptable salt thereof as an active ingredient: wherein X and Y independently represent a hydrogen atom, a halogen atom, a trihalomethyl group, a dihalomethyl group, a monohalomethyl group, a methoxy group, a hydroxyl group, or an alkyl group having 1 to 3 carbon atoms; R1, R2, R3 and R4 independently represent a hydrogen atom, a hydroxyl group, an alkoxyl group having 1 to 3 carbon atoms, or an alkyl group having 1 to 3 carbon atoms; R5 represents a hydrogen atom, an alkyl group having 1 to 5 carbon atoms, or an alkylene group which has 2 to 4 carbon atoms and can bind to a carbon atom other than carbon atoms that bind to a nitrogen atom on the cyclohexyl ring to form a ring; n represents an integer of 1 to 5; and Z represents a sulfur atom, a carbon atom, or an oxygen atom.

    摘要翻译： 公开了一种含有苯基的新型环己胺衍生物，其可用作新的σ受体配体。 还公开了伴有中枢神经系统病症的疾病的治疗剂，其包含该化合物作为活性成分。 治疗剂包括由通式[1]表示的化合物或其药理学上可接受的盐作为活性成分：其中X和Y独立地表示氢原子，卤素原子，三卤代甲基，二卤代甲基，单卤代甲基， 甲氧基，羟基或碳原子数1〜3的烷基， R1，R2，R3和R4独立地表示氢原子，羟基，具有1至3个碳原子的烷氧基或具有1至3个碳原子的烷基; R5表示氢原子，碳原子数1〜5的烷基或碳原子数2〜4的亚烷基，可以与结合于环己基环上的氮原子的碳原子以外的碳原子结合形成 戒指; n表示1〜5的整数， Z表示硫原子，碳原子或氧原子。

    Piperazine Derivatives
    8.
    发明申请
    Piperazine Derivatives 审中-公开
    哌嗪衍生物

    公开(公告)号：US20090221607A1

    公开(公告)日：2009-09-03

    申请号：US12223444

    申请日：2007-01-23

    申请人： Connie L. Sun ,  Xiaoyuan Li

    发明人： Connie L. Sun ,  Xiaoyuan Li

    IPC分类号： A61K31/495 ,  C07D241/04

    CPC分类号： C07D295/088

    摘要： Compounds of general formula (I) in which R1, A1, A2 and R2 have any of the meanings given in the specification, have affinity for sigma receptors and are useful in the treatment of disorders of the central nervous system.

    摘要翻译： 其中R1，A1，A2和R2具有本说明书中给出的任何含义的通式（I）的化合物对σ受体具有亲和力，并且可用于治疗中枢神经系统疾病。

    Sigma ligands for neuronal regeneration and functional recovery
    10.
    发明申请
    Sigma ligands for neuronal regeneration and functional recovery 审中-公开
    Sigma配体用于神经元再生和功能恢复

    公开(公告)号：US20110015209A1

    公开(公告)日：2011-01-20

    申请号：US12923504

    申请日：2010-09-24

    申请人： Mehrdad Shamloo ,  Donna Oksenberg ,  Roman Urfer

    发明人： Mehrdad Shamloo ,  Donna Oksenberg ,  Roman Urfer

    IPC分类号： A61K31/495 ,  A61P25/00

    CPC分类号： A61K31/00 ,  A61K31/438 ,  A61K31/495 ,  C07D295/096

    摘要： The invention discloses methods and compositions useful for facilitating neuronal regeneration and functional recovery in neurodegenerative diseases. The methods and compositions utilize ligands for the sigma receptor, wherein the ligand is preferably AGY-94806, or salts, or solvates thereof. These molecules can be delivered alone or in combination with agents which treat or prevent neurodegenerative diseases such as those caused by multiple sclerosis. In other methods, the sigma receptor ligands are administered after MS to facilitate functional recovery. The administration of the sigma receptor ligands causes fasted functional recovery.

    摘要翻译： 本发明公开了用于促进神经退行性疾病中的神经元再生和功能恢复的方法和组合物。 所述方法和组合物利用了σ受体的配体，其中配体优选为AGY-94806，或其盐或溶剂化物。 这些分子可单独递送或与治疗或预防神经变性疾病如由多发性硬化引起的疾病的药物组合递送。 在其他方法中，σ受体配体在MS后施用以促进功能恢复。 σ受体配体的施用引起禁食功能恢复。